PDCD1 and neoplasm: Moreover, Dasatinib combined with anti-PD-1 has been shown to reduce tumor burden and improve overall survival in preclinical models of Philadelphia chromosome-positive acute lymphoblastic leukemia, colorectal cancer, and non-small-cell lung cancer [124,125,126].